 Eloxx Pharmaceuticals, Inc. ELOX, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today provided an update on progress in its Phase 2 clinical programs and its pipeline of novel ERSG eukaryotic ribosomal selective glycoside compounds. The Phase 2 Cystic Fibrosis clinical trial program for ELX-02 is actively dosing patients in the U.S. and Israel and continuing to enroll patients at leading global investigator sites. 